Information on Lung Cancer: Patient Overview
Share
For patients newly facing a lung cancer diagnosis, the volume of information can be overwhelming. This light guide gives a clear overview of the disease, its types, treatment options, and what to expect.
Two Major Types: NSCLC and SCLC
Lung cancer divides into two broad categories:
- Non-small cell lung cancer (NSCLC): 85% of cases. Subtypes include adenocarcinoma (most common), squamous cell carcinoma, large cell carcinoma.
- Small cell lung cancer (SCLC): 15% of cases. Neuroendocrine origin. More aggressive but more responsive to chemotherapy initially.
The histological type significantly affects treatment.
Stages and What They Mean
Using the TNM system (IASLC 9th edition):
- Stage IA: tumor ≤3 cm, no nodes, no distant disease. 5-year survival 70-80%.
- Stage IB: 3-4 cm or visceral pleural invasion. 5-year survival 60-70%.
- Stage IIA-IIB: 4-7 cm or N1 nodes. 5-year survival 40-60%.
- Stage IIIA: N2 nodes or larger tumor. 5-year survival 25-40%.
- Stage IIIB: N3 nodes or other locally advanced. 5-year survival 15-25%.
- Stage IIIC-IV: extensive locally advanced or metastatic. 5-year survival 5-15%.
Common Symptoms
Lung cancer is often asymptomatic until later stages. When symptoms appear:
- Persistent cough (3+ weeks)
- Hemoptysis (coughing up blood)
- Chest pain
- Shortness of breath
- Unexplained weight loss
- Fatigue
- Hoarseness
- Recurrent unilateral pneumonia
In screening, lung cancer is often detected before symptoms develop — this is the goal of LDCT screening for high-risk smokers.
Treatment Options by Stage
Standard treatments aligned to stage:
| Stage | Standard treatment |
|---|---|
| IA-IB | Surgical resection (lobectomy or segmentectomy) |
| IIA-IIB | Surgical resection + adjuvant chemotherapy ± immunotherapy |
| IIIA (N2) | Combined chemoradiation + durvalumab consolidation, OR neoadjuvant chemo-IO + surgery |
| IIIB-IIIC | Chemoradiation + durvalumab |
| IVA (oligometastatic) | Systemic therapy + local consolidation |
| IVB (multi-site) | Systemic therapy: targeted, immunotherapy, or chemo |
Modern treatment depends heavily on molecular markers and PD-L1 status.
For coordinating treatment planning with a multidisciplinary team, our team can help.
Molecular Testing
For non-squamous NSCLC, comprehensive molecular testing is standard:
- EGFR mutations (esp. exon 19 deletion, L858R)
- ALK rearrangements
- ROS1 rearrangements
- KRAS G12C
- BRAF V600E
- HER2 mutations
- MET exon 14 skipping
- RET rearrangements
- NTRK fusions
- PD-L1 expression
Targetable mutations dramatically change treatment options and prognosis.
Important Treatment Players
Major drugs by category:
- TKIs for EGFR: osimertinib, gefitinib, erlotinib
- TKIs for ALK: alectinib, lorlatinib, brigatinib
- TKIs for ROS1: crizotinib, entrectinib
- TKIs for KRAS G12C: sotorasib, adagrasib
- Immunotherapy: pembrolizumab, nivolumab, atezolizumab, durvalumab
- Chemotherapy: cisplatin, carboplatin, pemetrexed, paclitaxel
Treatment is often combinations (chemo + immunotherapy) rather than single agents.
Where to Get Care
For self-pay or international patients seeking quality lung cancer care:
- United States: NCI-designated comprehensive cancer centers (MD Anderson, Sloan Kettering, Mayo, Cleveland)
- United Kingdom: Royal Marsden, Christie, Bart's
- Mainland China: Shanghai Chest Hospital, Sun Yat-sen Cancer Center, PUMC Beijing, Fudan SCC, Cancer Hospital CAMS Beijing
- Asia: Tata Memorial India, Singapore General Hospital, NCC Tokyo
Frequently Asked Questions
Will I survive my lung cancer?
Depends entirely on stage at diagnosis. Stage I has 70-80% 5-year survival. Stage IV has 5-15%. Modern targeted therapy and immunotherapy have substantially improved outcomes for advanced disease over the last decade.
Do I need molecular testing?
Yes for non-squamous NSCLC. Modern treatment decisions depend on molecular markers. Don't begin systemic therapy without at least EGFR, ALK, and PD-L1 results.
Can I get second opinion abroad?
Yes. Teleradiology and second-opinion pathology are widely available. Send DICOM imaging and pathology slides.
What if my cancer doesn't have a targetable mutation?
Modern treatment combines chemotherapy with immunotherapy. Response rates depend on PD-L1 expression and tumor mutation burden.
Need Help Booking?
SinoCareLink can pre-book multidisciplinary lung cancer consultation at a top Chinese cancer center, coordinate molecular testing, translate reports, and arrange airport pickup. Contact us for a free consultation.